英語ページ

Publications 2021

  1. Narita, T., Hatakeyama, S., Narita, S., Takahashi, M., Sakurai, T., Kawamura, S., Hoshi, S., Shimoda, J., Kawaguchi, T., Ishidoya, S., Mitsuzuka, K., Arai, Y., Ito, A., Tsuchiya, N., Habuchi, T., Ohyama, C. (2021) Therapeutic effects of the combined androgen blockade therapy versus luteinizing hormone-releasing hormone analog monotherapy in patients with hormone naïve metastatic prostate cancer: a multi-institutional comparative analysis. Transl. Androl. Urol., 10, 417-425.
  2. Narita, S., Obara, T., Ishikawa, N., Suzuki, Y., Habuchi, T.(2021)Cavernous branched nerve regeneration using non-tubular artificial nerve sheets using freeze-dried alginate gel combined with polyglycolic acid mesh in a rat model. Sex. Med., 9, 100308.
  3. Narita, T., Hatakeyama, S., Numakura, K., Kobayashi, M., Muto, Y., Saito, M., Narita, S., Tanaka, T., Noro, D., Tokui, N., Yoneyama, T., Hashimoto, Y., Habuchi, T., Ohyama, C. (2021) Comparison of pembrolizumab with conventional chemotherapy after first-line platinum-based chemotherapy for advanced urothelial carcinoma in real-world practice: A multicenter retrospective study. Int. J. Urol., 28, 899-905.
  4. Narita, S., Saito, M., Numakura, K., Habuchi, T. (2021) Incidence, etiology, prevention and management of ureteroenteric strictures after robot-assisted radical cystectomy: a review of published evidence and personal experience. Curr. Oncol., 28, 4109-4117.
  5. Numakura, K., Muto, Y., Naito, S., Hatakeyama, S., Kato, R., Koguchi, T., Kojima, T., Kawasaki, Y., Kandori, S., Kawamura, S., Arai, Y., Ito, A., Nishiyama, H., Kojima, Y., Obara, W., Ohyama, C., Tsuchiya, N., Habuchi, T. (2021) Outcomes of axitinib versus sunitinib as first-line therapy to patients with metastatic renal cell carcinoma in the immune-oncology era. Cancer Med., 10,5839-5846.
  6. Yamamoto, R., Saito, M., Abe, K., Saito, T., Sagehashi, R., Nara, T., Numakura, K., Narita, S., Satoh, S., Habuchi, T. (2021) Anaphylaxis induced by intravenous tacrolimus administration during kidney transplant surgery: A Case Report. Transplant. Proc., 53, 1292-1294.
  7. Huang, M., Narita, S., Koizumi, A., Nara, T., Numakura, K., Satoh, S., Nanjo, H., Habuchi, T. (2021) Macrophage inhibitory cytokine-1 induced by a high-fat diet promotes prostate cancer progression by stimulating tumor-promoting cytokine production from tumor stromal cells. Cancer Commun. (Lond), 41, 389-403.
  8. Huang, M., Koizumi, A., Narita, S., Nakanishi, H., Sato, H., Kashima, S., Nara, T., Kanda, S., Numakura, K., Saito, M., Satoh, S., Nanjo, H., Sasaki, T., Habuchi, T. (2021) Altering phosphoinositides in high-fat diet-associated prostate tumor xenograft growth. MedComm, 2, 756-764.
  9. Kobayashi, M., Narita, S., Matsui, Y., Kanda, S., Hidaka, Y., Abe, H., Tsuzuki, T., Ito, K., Kojima, T., Kato, M., Hatakeyama, S., Matsushita, Y., Naito, S., Shiga, M., Miyake, M., Muro, Y., Nakanishi, S., Kato, Y., Shibuya, T., Hayashi, T., Yasumoto, H., Yoshida, T., Uemura, M., Taoka, R., Kamiyama, M., Morita, S., Habuchi, T., Ogawa, O., Nishiyama, H., Kitamura, H., Kobayashi, T. (2021) Impact of histological variants on outcomes in patients with urothelial cancer treated with pembrolizumab: a propensity score matching analysis. BJU. Int., 10, 15510.
  10. Kobayashi, M., Fujiyama, N., Tanegashima, T., Narita, S., Yamamoto, Y., Fujimoto, N., Ueda, S., Takeuchi, A., Numakura, K., Habuchi, T., Matsuyama, H., Eto, M., Shiota, M. (2021) Effect of HLA genotype on intravesical recurrence after bacillus Calmette-Guérin therapy for non-muscle-invasive bladder cancer. Cancer Immunol. Immunother. 71, 727-736.
  11. Muto, Y., Narita, S., Hatakeyama, S., Maita, S., Chiba, S., Kubo, K., Aoyama, Y., Ito, R., Takahashi, Y., Takahashi, S., Nakamura, K., Honma, N., Sato, H., Koizumi, A., Igarashi, R., Okane, K., Ishida, T., Horikawa, Y., Kumazawa, T., Akihama, S., Shimoda, J., Suzuki, T., Ohyama, C., Habuchi, T. (2021) Short-term outcomes of risk-adapted upfront docetaxel administration in patients with metastatic hormone-sensitive prostate cancer: a multicenter prospective study in Japan. Med. Oncol., 38, 37.
  12. Hatakeyama, S., Naito, S., Numakura, K., Kato, R., Koguchi, T., Kojima, T., Kawasaki, Y., Kandori, S., Kawamura, S., Tsushima, E., Nishiyama, H., Ito, A., Kojima, Y., Habuchi, T., Obara, W., Tsuchiya, N., Ohyama, C. (2021) Impact of cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma receiving systemic tyrosine kinase inhibitor therapy: A multicenter retrospective study. Int. J. Urol., 28, 369-375.
  13. Hatakeyama, S., Narita, S., Okita, K., Narita, T., Iwamura, H., Fujita, N., Inokuchi, J., Matsui, Y., Kitamura, H., Ohyama, C. (2022) Management of bladder cancer in older patients. Jpn. J. Clin. Oncol., 52, 203-213.
  14. Hatakeyama, S., Naito, S., Numakura, K., Kato, R., Koguchi, T., Kojima, T., Kawasaki, Y., Kandori, S., Kawamura, S., Tsushima, E., Nishiyama, H., Ito, A., Kojima, Y., Habuchi, T., Obara, W., Tsuchiya, N., Ohyama, C. (2021) Impact of cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma receiving systemic tyrosine kinase inhibitor therapy: A multicenter retrospective study. Int. J. Urol., 28, 369-375.
  15. Kanda, S., Inoue, T., Nakajima, S., Sagehashi, R., Nara, T., Numakura, K., Saito, M., Narita, S., Tsuchiya, N., Habuchi, T. (2021) Comparison of parenchymal volume loss assessed by three-dimensional computed tomography volumetry and renal functional recovery between conventional and robot-assisted laparoscopic partial nephrectomy. Asian J. Endosc. Surg., 15, 63-69.
  16. Takayama, K., Narita, S., Terai, Y., Saito, R., Habuchi, T. (2021) Cancer antigen 15-3 serum level as a biomarker for advanced micropapillary urothelial carcinoma of the bladder: a case report. Case Rep. Oncol., 14, 1019-1024.
  17. Matsuda, Y., Narita, S., Okubo, T., Mitsuzuka, K., Hatakeyama, S., Koizumi, A., Koie, T., Kawamura, S., Tochigi, T., Ito, A., Ohyama, C., Arai, Y., Habuchi, T. (2021) Impact of nerve-sparing status on positive surgical margin location and biochemical recurrence in patients with prostate cancer post radical prostatectomy. Ann. Surg. Oncol., 28, 5341-5348.
  18. Okita, K., Hatakeyama, S., Naito, S., Numakura, K., Kato, R., Koguchi, T., Kojima, T., Kawasaki, Y., Kandori, S., Kawamura, S., Nishiyama, H., Ito, A., Kojima, Y., Habuchi, T., Obara, W., Tsuchiya, N., Ohyama, C. (2021) External validation of the REMARCC model for the selection of cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma: A multicenter retrospective study. Urol. Oncol., 39, 836.
  19. Shiota, M., Terada, N., Saito, T., Yokomizo, A., Kohei, N., Goto, T., Kawamura, S., Hashimoto, Y., Takahashi, A., Kimura, T., Tabata, KI., Tomida, R., Hashimoto, K., Sakurai, T., Shimazui, T., Sakamoto, S., Kamiyama, M., Tanaka, N., Mitsuzuka, K., Kato, T., Narita, S., Yasumoto, H., Teraoka, S., Kato, M., Osawa, T., Nagumo, Y., Matsumoto, H., Enokida, H., Sugiyama, T., Kuroiwa, K., Inoue, T., Mizowaki, T., Kamoto, T., Kojima, T., Kitamura, H., Sugimoto, M., Nishiyama, H., Eto, M.(2021) Differential prognostic factors in low- and high-burden de novo metastatic hormone-sensitive prostate cancer patients. Cancer Sci., 112, 1524-1533.
  20. Shiota, M., Akamatsu, S., Narita, S., Sumiyoshi, T., Fujiwara, M., Uchiumi, T., Ogawa, O., Habuchi, T., Eto, M. (2021) The association between missense polymorphisms in SRD5A2 and HSD3B1 and treatment failure with abiraterone for castration-resistant prostate cancer. Pharmacogenomics J., 21, 440-445.
  21. Shiota, M., Narita, S., Habuchi, T., Eto, M. (2021) Validated prognostic significance of YB-1 genetic variation in metastatic prostate cancer. Pharmacogenomics J., 21, 102-105.
  22. Soria, F., Laguna, MP., Roupret, M., Garcia-Marchinena, P., Gonzalez, MS., Habuchi, T., Erkan, E, Ng, A., Gontero, P., de la Rosette, J. (2021) Flexible fibre optic vs digital ureteroscopy and enhanced vs unenhanced imaging for diagnosis and treatment of upper tract urothelial carcinoma (UTUC): results from the Clinical Research Office of the Endourology Society (CROES)-UTUC registry. BJU. Int., 28, 734-743.
  23. Inokuchi, J., Kuroiwa, K., Nishiyama, H., Kojima, T., Kakehi, Y., Sugimoto, M., Takenaka, A., Fujimoto, K., Yamaguchi, R., Habuchi, T., Hashine, K., Mizusawa, J., Eba, J., Naito, S. (2021) Significance of the timing of ureteral ligation on prognosis during radical nephroureterectomy for upper urinary tract urothelial cancer. Int. J. Urol., 28, 208-214.
  24. Kido, K., Hatakeyama, S., Numakura, K., Tanaka, T., Oikawa, M., Noro, D., Hosogoe, S., Narita, S., Inoue, T., Yoneyama, T., Ito, H., Nishimura, S., Hashimoto, Y., Kawaguchi, T., Habuchi, T., Ohyama, C. (2021) Comparison of nivolumab plus ipilimumab with tyrosine kinase inhibitors as first-line therapies for metastatic renal-cell carcinoma: a multicenter retrospective study. Int. J. Clin. Oncol., 26, 154-162.
  25. Iwamura, H., Hatakeyama, S., Narita, S., Arai, Y., Habuchi, T., Ohyama, C. (2021) Prognosis of metastatic castration-resistant prostate cancer in the era of the second-generation androgen receptor-targeted agents: a retrospective multicenter study. Int. J. Urol., 28, 125-127.
  26. Okamoto, T., Noro, D., Hatakeyama, S., Narita, S., Mitsuzuka, K., Sakurai, T., Kawamura, S., Hoshi, S., Shimoda, J., Tanaka, T., Kawaguchi, T., Ishidoya, S., Ito, A., Tsuchiya, N., Habuchi, T., Ohyama, C. (2021) Impact of pretreatment anemia on upfront abiraterone acetate therapy for metastatic hormone-sensitive prostate cancer: a multicenter retrospective study. BMC. Cancer, 25, 605.
  27. Naito, S., Kato, T., Numakura, K., Hatakeyama, S., Koguchi, T., Kandori, S., Kawasaki, Y., Adachi, H., Kato, R., Narita, S., Yamamoto, H., Ogawa, S., Kawamura, S., Obara, W., Ito, A., Nishiyama, H., Kojima, Y., Ohyama, C., Habuchi, T., Tsuchiya, N. (2021) Prognosis of Japanese metastatic renal cell carcinoma patients in the targeted therapy era. Int. J. Clin. Oncol., 26, 1947-1954.
  28. Yoneyama, T., Yamamoto, R., Sutoh, H., Yoneyama, M., Tobisawa, Y., Hatakeyama, S., Narita, T., Kodama, H., Momota, M., Ito, H., Narita, S., Tsushima, F., Mitsuzuka, K., Yoneyama, T., Hashimoto, Y., Duivenvoorden, W., Pinthus, JH., Kakeda, S., Ito, A., Tsuchiya, N., Habuchi, T., Ohyama, C. (2021) Characteristics of α2,3-sialyl N-glycosylated PSA as a biomarker for clinically significant prostate cancer in men with elevated PSA level. Prostate, 81, 1411-1427.
  29. Mizuno, K., Sumiyoshi, T., Okegawa, T., Terada, N., Ishitoya, S., Miyazaki, Y., Kojima, T., Katayama, H., Fujimoto, N., Hatakeyama, S., Shiota, M., Yoshimura, K., Matsui, Y., Narita, S., Matsumoto, H., Kurahashi, R., Kanno, H., Ito, K., Kimura, H., Kamiyama, Y., Sunada, T., Goto, T., Kobayashi, T., Yamada, H., Tsuchiya, N., Kamba, T., Matsuyama, H., Habuchi, T., Eto, M., Ohyama, C., Ito, A., Nishiyama, H., Okuno, H., Kamoto, T., Fujimoto, A., Ogawa, O., Akamatsu, S. (2021) Clinical impact of detecting low-frequency variants in cell-free DNA on treatment of castration-resistant prostate cancer. Clin. Cancer Res., 27, 6164-6173.
  30. Okuyama, Y., Hatakeyama, S., Numakura, K., Narita, T., Tanaka, T., Miura, Y., Sasaki, D., Noro, D., Tokui, N., Okamoto, T., Yamamoto, H., Narita, S., Yoneyama, T., Hashimoto, Y., Habuchi, T., Ohyama, C. (2021) Prognostic impact of proton pump inhibitors for immunotherapy in advanced urothelial carcinoma, BJUI. Compass, 3, 154-161.
  31. Nose, N., Nogami, S., Koshino, K., Chen, X., Werner, RA., Kashima, S., Rowe, SP., Lapa, C., Fukuchi, K., Higuchi, T. (2021) [18F] FDG-labelled stem cell PET imaging in different route of administrations and multiple animal species. Sci. Rep., 11, 10896.
  32. Tomita, Y., Kimura, G., Fukasawa, S., Numakura, K., Sugiyama, Y., Yamana, K., Naito, S., Kaneko, H., Tajima, Y., Oya, M. (2021) Subgroup analysis of the AFTER I-O study: a retrospective study on the efficacy and safety of subsequent molecular targeted therapy after immune-oncology therapy in Japanese patients with metastatic renal cell carcinoma. Jpn. J. Clin. Oncol., 51, 1656-1664.
  33. Miyake, M., Iida, K., Nishimura, N., Miyamoto, T., Fujimoto, K., Tomida, R., Matsumoto, K., Numakura, K., Inokuchi, J., Morizane, S., Yoneyama, T., Matsumura, Y., Abe, T., Inoue, M., Yamada, T., Terada, N., Hirao, S., Uemura, M., Matsushita, Y., Taoka, R., Kobayashi, T., Kojima, T., Matsui, Y., Kitamura, H., Nishiyama, H. (2021) Non-maintenance intravesical Bacillus Calmette-Guérin induction therapy with eight doses in patients with high- or highest-risk non-muscle invasive bladder cancer: a retrospective non-randomized comparative study. BMC. Cancer, 21, 266.
  34. Tomita, Y., Kimura, G., Fukasawa, S., Numakura, K., Sugiyama, Y., Yamana, K., Naito, S., Kabu, K., Tajima, Y., Oya, M. (2021) Efficacy and safety of subsequent molecular targeted therapy after immuno-checkpoint therapy, retrospective study of Japanese patients with metastatic renal cell carcinoma (AFTER I-O study). Jpn. J. Clin. Oncol., 51, 966-975.

メニューを開く